Pitavastatin is a statin medication that lowers LDL cholesterol and ApoB by inhibiting HMG-CoA reductase, a key enzyme in cholesterol synthesis. Its primary healthspan relevance is the significant reduction of atherosclerotic cardiovascular disease (ASCVD) risk, a leading cause of age-related mortality. Unlike some other statins, evidence suggests it has a neutral or potentially beneficial effect on glucose metabolism, making it a compelling choice for individuals concerned with insulin resistance.
Verdict
A top-tier choice for lowering ApoB/LDL-C with a favorable metabolic profile.
HEALTHSPAN IMPACT
Foundational
RISK LEVEL
Moderate
EVIDENCE GRADE
A
MONTHLY COST
$15 - $60
Protocol
- Typical daily dosage ranges from 1 mg to 4 mg, taken orally, to target specific ApoB or LDL-C levels.
Flags
- Myalgia (muscle pain) is the most commonly reported side effect.
- Rare but serious risks include rhabdomyolysis (severe muscle breakdown) and liver injury.
- Interacts with cyclosporine, certain fibrates (like gemfibrozil), and some HIV/HCV protease inhibitors.
- Considered to have a lower risk of inducing new-onset diabetes compared to other statins.